GLAB — Gemina Laboratories Income Statement
0.000.00%
Last trade - 00:00- CA$65.09m
- CA$66.36m
Annual income statement for Gemina Laboratories, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | 2025 January 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.543 | 3.01 | 2.62 | 3.56 | 3.89 |
| Operating Profit | -0.543 | -3.01 | -2.62 | -3.56 | -3.89 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.834 | -4.73 | -5.98 | -5.22 | -4.07 |
| Net Income After Taxes | -0.834 | -4.73 | -5.98 | -5.22 | -4.07 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.834 | -4.73 | -5.98 | -5.22 | -4.07 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.834 | -4.73 | -5.98 | -5.22 | -4.07 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.017 | -0.099 | -0.099 | -0.072 | -0.055 |
| Dividends per Share |